227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
75 citations
,
March 2023 in “JAMA Dermatology” This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.
20 citations
,
February 2022 in “British Journal of Dermatology” This study found that people with alopecia areata have higher rates of depression and anxiety, leading to increased mental health treatment burden, more time off work, and higher unemployment compared to the general population.
22 citations
,
November 2021 in “Dermatology and Therapy” This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.
117 citations
,
July 2021 in “British Journal of Dermatology” This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.
38 citations
,
March 2021 in “JAMA Dermatology” This cross-sectional survey study found that stigmatizing attitudes toward people with alopecia are present in various social and professional settings, with stigma levels varying by alopecia severity and perceptions of its medical nature.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” This study found that alopecia areata significantly impacts emotional and psychological well-being, relationships, and lifestyles, highlighting the need for increased awareness and effective treatments.
63 citations
,
March 2020 in “Clinical Cosmetic and Investigational Dermatology” This study suggests that the prevalence of alopecia areata in the US remains similar to high estimates from the 1970s, with significant implications for quality of life.
86 citations
,
January 2020 in “British Journal of Dermatology” This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
128 citations
,
February 2016 in “British Journal of Dermatology” This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.
25 citations
,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” This study found that alopecia areata negatively affects patients' quality of life, though less severely than psoriasis, atopic dermatitis, and onychomycosis.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
45 citations
,
May 2012 in “CRC Press eBooks” The book helps doctors better understand and treat hair disorders due to gaps in their training.
48 citations
,
April 2010 in “Journal of the European Academy of Dermatology and Venereology” This article reviews gender differences in skin disorders, highlighting variations in disease prevalence and type between sexes, but reports no new findings, emphasizing potential implications for prevention and treatment strategies.
